HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage non-Hodgkin's lymphoma patients

Files in This Item:
EJH77-5.pdf333.42 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage non-Hodgkin's lymphoma patients
Authors: Toubai, Tomomi Browse this author
Tanaka, Junji Browse this author →KAKEN DB
Ota, Shuichi Browse this author
Fukuhara, Takashi Browse this author
Hashino, Satoshi Browse this author →KAKEN DB
Kondo, Takeshi Browse this author →KAKEN DB
Shono, Yusuke Browse this author
Morioka, Masanobu Browse this author
Kawamura, Tsugumichi Browse this author
Masauzi, Nobuo Browse this author
Kakinoki, Yasutaka Browse this author
Kobayashi, Hajime Browse this author
Kunieda, Yasuyuki Browse this author
Kasai, Masaharu Browse this author
Kurosawa, Mitsutoshi Browse this author
Asaka, Masahiro Browse this author
Imamura, Masahiro Browse this author
Keywords: IL-12
IL-12 p40
IL-12 p35
non-Hodgkin’s lymphoma
Issue Date: Nov-2006
Publisher: Blackwell Publishing
Journal Title: European Journal Of Haematology
Volume: 77
Issue: 5
Start Page: 403
End Page: 409
Publisher DOI: 10.1111/j.1600-0609.2006.00746.x
PMID: 16930137
Abstract: Interleukin (IL)-12 is a 70-kDa cytokine comprised of two disulfide-linked proteins (p35 and p40) and is essential for the initiation of effective immune response. Granulocyte-colony stimulating factor (G-CSF) affects the balance in the production of anti-inflammatory cytokines. We investigated the serum IL-12 p40 and IL-12 Mix (p40 and p70) production in 28 patients with B-cell lineage non-Hodgkin's lymphoma (NHL) treated with chemotherapy (e.g., CHOP regimen) with or without G-CSF administration and eight healthy volunteers. We found that serum levels of IL-12 p40 (191.2 ± 150.0 pg/mL) and IL-12 Mix (277.4 ± 274.5 pg/mL) in the patients before chemotherapy were higher than those in the healthy volunteers (IL-12 p40: 76.4 ± 25.3 pg/mL, IL-12 Mix: 48.5 ± 33.4 pg/mL) (P = 0.04 and 0.02, respectively). Next, we examined the serum IL-12 p40 and IL-12 Mix levels in nine patients receiving chemotherapy with administration of G-CSF (CG group, n = 9) and without G-CSF (C group, n = 9). Serum IL-12 p40 and IL-12 Mix levels were decreased on 10 d after chemotherapy in both groups, and those in CG groups were significantly lower than those in C group. These results indicated that administration of G-CSF decreased serum IL-12 p40 and IL-12 Mix levels. Overall survival (OS) at 24 months was not significantly different in the two groups (58.3% in group C vs. 80.0% in group CG, P = 0.67). However, the survival rate of patients at clinical stages III and IV in CG group (n = 6, 66.0%) was significantly better than that of patients in C group (n = 4, 25.0%) (P = 0.02). Long-term administration of G-CSF appears to influence the survival rate by reducing immunosuppressive IL-12 p40 production.
Rights: The definitive version is available at
Type: article (author version)
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 東梅 友美

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


Feedback - Hokkaido University